ES2187719T3 - Derivados difluoroprostaglandinas y su aplicacion. - Google Patents

Derivados difluoroprostaglandinas y su aplicacion.

Info

Publication number
ES2187719T3
ES2187719T3 ES97122702T ES97122702T ES2187719T3 ES 2187719 T3 ES2187719 T3 ES 2187719T3 ES 97122702 T ES97122702 T ES 97122702T ES 97122702 T ES97122702 T ES 97122702T ES 2187719 T3 ES2187719 T3 ES 2187719T3
Authority
ES
Spain
Prior art keywords
similar
difluoroprostaglandinas
derivatives
application
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97122702T
Other languages
English (en)
Spanish (es)
Inventor
Eiichi Santen Pharma Shirasawa
Masaaki Santen Pharma Kageyama
Tadashi Santen Pharma Nakajima
Takashi Asahi Glass Com Nakano
Nobuaki Asahi Glass Compa Mori
Hideshi Asahi Glass C Sasakura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187719(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Application granted granted Critical
Publication of ES2187719T3 publication Critical patent/ES2187719T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
ES97122702T 1996-12-26 1997-12-22 Derivados difluoroprostaglandinas y su aplicacion. Expired - Lifetime ES2187719T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (1)

Publication Number Publication Date
ES2187719T3 true ES2187719T3 (es) 2003-06-16

Family

ID=27301396

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97122702T Expired - Lifetime ES2187719T3 (es) 1996-12-26 1997-12-22 Derivados difluoroprostaglandinas y su aplicacion.

Country Status (16)

Country Link
US (2) US5886035A (https=)
EP (1) EP0850926B1 (https=)
JP (2) JP3480549B2 (https=)
KR (1) KR100526282B1 (https=)
CN (1) CN1108289C (https=)
AT (1) ATE225770T1 (https=)
CA (1) CA2225761C (https=)
DE (2) DE69716226T2 (https=)
DK (1) DK0850926T3 (https=)
ES (1) ES2187719T3 (https=)
FR (1) FR11C0020I2 (https=)
LU (1) LU91943I2 (https=)
NL (1) NL300407I2 (https=)
NO (2) NO317060B1 (https=)
PT (1) PT850926E (https=)
TW (1) TW536534B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
WO2001055102A1 (fr) * 2000-01-28 2001-08-02 Asahi Glass Company, Limited Nouveau derive difluoroprostaglandine
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
EP1532981B1 (en) * 2002-08-23 2007-09-26 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
CA2707068A1 (en) 2002-09-09 2004-03-18 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
ATE450264T1 (de) * 2003-07-31 2009-12-15 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
CA2731269C (en) * 2003-12-08 2013-01-08 Qualcomm Incorporated High data rate interface with improved link synchronization
US20080139648A1 (en) * 2004-12-09 2008-06-12 Santen Pharmaceutical Co., Ltd. Product Containing Prostaglandin Having Fluorine Atom In Its Molecule
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
KR101396731B1 (ko) * 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 Ｆ２ａ 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
JP5100025B2 (ja) * 2005-03-31 2012-12-19 旭硝子株式会社 プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
CN101160128B (zh) 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
EP1917239A1 (en) * 2005-06-29 2008-05-07 Pfizer, Inc. Fluoroprostaglandins nitroderivatives
EP2735566A1 (en) * 2006-02-07 2014-05-28 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
WO2010027040A1 (ja) * 2008-09-04 2010-03-11 参天製薬株式会社 １５，１５－ジフルオロプロスタグランジンＦ2α誘導体を有効成分として含有する毛髪成長促進剤
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2012018324A1 (en) 2010-08-02 2012-02-09 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
EP3378480A1 (en) 2011-01-19 2018-09-26 Topokine Therapeutics, Inc. Methods and compositions for treating obesity
ES2684351T3 (es) 2011-02-04 2018-10-02 Kowa Co., Ltd. Terapia farmacológica para prevenir o tratar glaucoma
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013118058A1 (en) * 2012-02-07 2013-08-15 Dr.Reddys Laboratories Limited Amine salts of prostaglandin analogs
CA2874288A1 (en) 2012-05-30 2013-12-05 Asahi Glass Company, Limited Composition for hair growth
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (https=) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103804195B (zh) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103819436A (zh) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 (3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
WO2015200425A1 (en) 2014-06-27 2015-12-30 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (ko) 2015-03-30 2016-10-10 연성정밀화학(주) 타플루프로스트의 제조방법
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
CN107226790A (zh) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 他氟前列素的制备方法
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
CN112851510B (zh) * 2021-01-27 2022-07-19 Ａｇｃ株式会社 他氟前列素的纯化方法
CN112832150B (zh) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 一种涵洞通道等立面垂直凿毛装置
CN116120268A (zh) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 一种他氟前列素中间体异构体杂质及其制备方法
CN117024324A (zh) * 2023-08-03 2023-11-10 南京华威医药科技集团有限公司 一种他氟前列素对映异构体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
ATE221048T1 (de) * 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
ES2159889T3 (es) * 1996-11-12 2001-10-16 Alcon Lab Inc 15-fluoro prostaglandinas utilizadas como hipotensores oculares.

Also Published As

Publication number Publication date
JP3480549B2 (ja) 2003-12-22
NO2009006I1 (no) 2009-03-16
ATE225770T1 (de) 2002-10-15
NL300407I2 (nl) 2010-03-01
DE69716226T2 (de) 2003-06-05
FR11C0020I1 (https=) 2011-07-29
JP2004002462A (ja) 2004-01-08
KR19980064718A (ko) 1998-10-07
DE69716226D1 (de) 2002-11-14
CN1187486A (zh) 1998-07-15
EP0850926A3 (en) 1999-06-16
US5886035A (en) 1999-03-23
EP0850926B1 (en) 2002-10-09
LU91943I2 (fr) 2012-04-16
US5985920A (en) 1999-11-16
CA2225761C (en) 2009-04-21
NL300407I1 (nl) 2009-11-02
EP0850926A2 (en) 1998-07-01
NO2009006I2 (no) 2012-03-05
NO976085L (no) 1998-06-29
CN1108289C (zh) 2003-05-14
DE122008000050I1 (de) 2009-01-29
KR100526282B1 (ko) 2006-05-17
DE122008000050I2 (de) 2011-06-16
JP3994074B2 (ja) 2007-10-17
PT850926E (pt) 2003-02-28
DK0850926T3 (da) 2003-02-17
FR11C0020I2 (fr) 2012-03-16
NO976085D0 (no) 1997-12-23
NO317060B1 (no) 2004-08-02
JPH1171344A (ja) 1999-03-16
TW536534B (en) 2003-06-11
CA2225761A1 (en) 1998-06-26

Similar Documents

Publication Publication Date Title
ES2187719T3 (es) Derivados difluoroprostaglandinas y su aplicacion.
HU913193D0 (en) 17betha-substituted 4-aza-5alpha-androstane-3-on derivatives, process for their production and for the production of medical preparations containing them
ATE384524T1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2152556T3 (es) Composiciones que contienen derivados del acido hidroperoxieicosatetraenoico y procedimientos de utilizacion en el tratamiento de trastornos de la sequedad ocular.
LV5483A3 (lv) Izohinolinija atvasinajumu iegusanas panemiens
TR199700711T1 (xx) Ciltten ge�erek v�cuda giren form�lasyon.
AU3159701A (en) Agent for dyeing keratin containing fibers
ES524680A0 (es) Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina.
CA2153549A1 (fr) Nouveau derive de benzothiadiazine, son procede de preparation et les compositions pharmeceutiques qui le contiennent
AR002260A1 (es) Compuestos derivados de acido [4-(indazol-3-il)-piperidin-1-il]-acetico, procedimiento para su preparacion, composicion farmacuetica que los contienen,el uso de los mismos en la preparacion de un agente terapeutico, metodo de tratamiento y compuestos intermediarios.
ES2196049T3 (es) Uso de 2-(2-alquilfenilamino)oxazolinas y -tiazolinas para la fabricacion de un medicamento con efecto alfa 2 adrenergico.
ZA863382B (en) Quinolylglycinamide derivatives,the process for preparation thereof and their therapeutic application as psychotropic drugs
ES2154757T3 (es) Derivados de tiopirano.
ES2119130T3 (es) Microbiocidas.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
ES2162919T3 (es) Piridilbisfosfonatos para uso como agente terapeutico.
KR970064604A (ko) 벤조피란 유도체 및 그의 심장질환 치료제로서의 용도
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.
SE8901149D0 (sv) Medel foer inducering respektive foerhindrande av pupillkonstriktion i oegat
AU540454B2 (en) Method for treating inflammation
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법